산삼약침 혈맥주입을 시행한 비소세포성폐암 환자 2례
Two Cases of Non-Small Cell Lung Cancer Treated with Intravenous Cultivated Wild Ginseng Extract
2
조회
0
다운로드
21
인용
0
참고문헌
키워드
초록
Objectives To investigate the therapeutic effects of intravenous cultivated wild ginseng(Panax ginseng C.A. Meyer) pharmacopuncture(CWGP) in treating patients with non-small cell lung cancer(NSCLC). Design Prospective case series. Setting This study was conducted at the East-West Cancer Center of Dunsan Oriental Hospital, Daejeon University. Patients Two non-small cell lung cancer patients. Intervention Two non-small cell lung cancer patients were injected CWGP(20mL/day) mixed with 0.9% normal saline(100mL) intravenously. Each patient received a total of 16 and 9 cycles, respectively. One cycle is composed of 14 days. Outcome Measures The effect of intravenous CWGP was measured by scanning with computed tomography(CT) after every 2 cycle and Positron emission tomography- computed tomography(PET/CT) after every 6 cycles. Response and progression was evaluated using the Response Evaluation Criteria in Solid Tumors(RECIST) Committee classification of complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD). Results They were treated with intravenous CWGP for 8 and 5 months respectively. time later, each tumor remains stable disease(SD) Conclusion These cases may give us a possibility that intravenous CWGP offers potential benefits for non-small cell lung cancer patients.
Abstract
Objectives To investigate the therapeutic effects of intravenous cultivated wild ginseng(Panax ginseng C.A. Meyer) pharmacopuncture(CWGP) in treating patients with non-small cell lung cancer(NSCLC). Design Prospective case series. Setting This study was conducted at the East-West Cancer Center of Dunsan Oriental Hospital, Daejeon University. Patients Two non-small cell lung cancer patients. Intervention Two non-small cell lung cancer patients were injected CWGP(20mL/day) mixed with 0.9% normal saline(100mL) intravenously. Each patient received a total of 16 and 9 cycles, respectively. One cycle is composed of 14 days. Outcome Measures The effect of intravenous CWGP was measured by scanning with computed tomography(CT) after every 2 cycle and Positron emission tomography- computed tomography(PET/CT) after every 6 cycles. Response and progression was evaluated using the Response Evaluation Criteria in Solid Tumors(RECIST) Committee classification of complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD). Results They were treated with intravenous CWGP for 8 and 5 months respectively. time later, each tumor remains stable disease(SD) Conclusion These cases may give us a possibility that intravenous CWGP offers potential benefits for non-small cell lung cancer patients.
참고문헌 (21)
- , 제 98차 대한 결핵 및 호흡기학회 춘계학술대회 (2004)
- 신순식, "산삼 감정기준의 객관성", pp.107~114 (2001), 東義韓醫硏
- 대한약침학회, "약침요법 시술 지침서", 대한약침학회, pp.13~203 (1999)
- 이종영, "血脈에 대한 문헌적 고찰", 대한약침학회지, 8(3), pp.11~19 (2005), 대한약침학회
- 권기록, "정맥주입용 산양산삼 증류약침이의 급성, 아급성 독성 실험 및 Sarcoma-180항암효과에 관한 실험적 연구", 대한약침학회지, 6(2), pp.7~27 (2003)
- 권기록, "정맥주입용 산삼약침이 인체에 미치는 영향에 관한 임상적 연구", 대한약침학회지, 7(1), pp.15~26 (2004)
- 박봉기, "6개월간 산삼약침요법을 시행받은 ⅢB기 편평세포폐암 환자에 대한 증례보고", 대한약침학회지, 10(3), pp.143~147 (2007), 대한약침학회
- 안용찬, "비소세포성폐암에 있어서 방사선치료의 역할", 제 98차 대한결핵 및 호흡기학회 춘계학술대회, pp.22~25 (2004)
- 박재갑, "종양학", pp.304~ (2003), 일조각
- 김명훈, "제4병기 비소세포폐암의 예후인자", 대한결핵 및 호흡기학회, 53, pp.380~ (2002)
- 북경중의학원, "중의학 임상병리", pp.572~ (1983), 성보사
- 강락원, "산삼약침 혈맥주입을 시행한 비소세포성폐암 환자 2례 17최영현, 감철우, 박동일. 길경 수용액 추출물에 의한인체 폐암세포의 성장억제 기전 연구", 2004년 대한한방내과학회 춘계학술대회, pp.62~72 (2004)
- 안창범, "약침용봉독성분 melittin의 영향에 의한 인체 폐암세포의apoptosis 유도", 대한침구학회지, 20, pp.93~106 (2003)
- 김정근, "폐암으로진단 받은 환자의 호흡곤란과 해수 호전 1례", 2005년 대한한방내과학회 추계학술회., pp.255~261 (2005)
- 곽정진, "김종석.비폐양허형 폐암횐자 1례에 대한 임상적 고찰", 대한한방내과학회지, 23(3), pp.486~496 (2002)
- 김재연, "폐암환자 1례에 대한 임상적 고찰", 대한한방내과학회지, 23(3), pp.144~152 (2005)
- Chen MW., "The effects of 20(R)-Rg3 on lung carcinoma A549 cell line and endogenous VEGF secreted by tumor cells", Sichuan Da Xue Xue Bao Yi Xue Ban, 37(1), pp.60~62 (2006)
- Chen MW., "The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell", Zhongguo Zhong Yao Za Zhi, 30(5), pp.357~360 (2005)
- Lu P., "Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer" (2008), Chin J Integr Med.
- Yoo HS., "The effects ofHangAmDan onAntimetastasis and preventing relapses, administered to 69 cancer patients", Korean J. Oriental Int. Med, 23(2), pp.165~173 (2002)
- Lee NH., "Changes of Serum VEGF, bFGF levels and platelet counts in 100 cancer patients treated with HangAmDan(HAD)", Korean J. Orient. Int. Med, 26(4), pp.753~760 (2005)